Is YMAB a buy or a sell?
The Discounted Cash Flow (DCF) valuation of Y-mAbs Therapeutics, Inc (YMAB) is (26.97) USD. With the latest stock price at 5.00 USD, the upside of Y-mAbs Therapeutics, Inc based on DCF is -639.4%. This means that YMAB is a sell according to the DCF valuation model.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 5.6% - 9.1% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (150.02) - (14.58) | (26.97) |
| Upside | -3100.4% - -391.6% | -639.4% |